El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

dc.contributor.authorPujana Genestar, M. Ángel
dc.contributor.authorTeulé-Vega, Àlex
dc.contributor.authorGEMO Study Collaborators
dc.contributor.authorEMBRACE Collaborators
dc.contributor.authorKConFab Investigators
dc.contributor.authorHEBON Investigators
dc.contributor.authorABCTB Investigators
dc.date.accessioned2021-04-12T15:30:12Z
dc.date.available2021-04-12T15:30:12Z
dc.date.issued2021-02-17
dc.date.updated2021-03-24T07:31:57Z
dc.description.abstractBreast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10-8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.
dc.format.extent22 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid33597508
dc.identifier.urihttps://hdl.handle.net/2445/176216
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/s41467-020-20496-3
dc.relation.ispartofNature Communications, 2021, vol. 12
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/223175/EU//COGS
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/634935/EU//BRIDGES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/633784/EU//B-CAST
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/310018/EU//IHCAP
dc.relation.urihttps://doi.org/10.1038/s41467-020-20496-3
dc.rightscc by (c) Coignard et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationCàncer de mama
dc.subject.classificationGenètica
dc.subject.otherBreast cancer
dc.subject.otherGenetics
dc.titleA case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
s41467-020-20496-3.pdf
Mida:
3.64 MB
Format:
Adobe Portable Document Format